Difference between revisions of "Encorafenib (Braftovi)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
Line 14: | Line 14: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
+ | [[Category:Mutation-specific medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] |
Revision as of 17:06, 10 January 2020
General information
Class/mechanism (from NCI Drug Dictionary): An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Binimetinib (Mektovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Also known as
- Code name: LGX818
- Brand name: Braftovi